Akihiko Uchiyama

Maebashi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 133 publications

Routine blood biomarkers associated with clinical response to tralokinumab in patients with atopic dermatitis: a 48-week real-world study in Japan.

Routine blood biomarkers associated with clinical response to tralokinumab in patients with atopic dermatitis: a 48-week real-world study in Japan.

Journal: European journal of dermatology : EJD

Published: September 05, 2026

Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).

Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).

Journal: European journal of dermatology : EJD

Published: May 25, 2026

Letter: Long-Term Safety and Effectiveness of Lebrikizumab Treatment for Moderate-to-Severe Atopic Dermatitis Stratified by Age Groups in Real-World Clinical Practice in Japan.

Letter: Long-Term Safety and Effectiveness of Lebrikizumab Treatment for Moderate-to-Severe Atopic Dermatitis Stratified by Age Groups in Real-World Clinical Practice in Japan.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: March 02, 2026

Sustainability of Early Responses and Achievement of Delayed Responses to Lebrikizumab in Atopic Dermatitis: A 48-Week Japanese Real-World Study.

Sustainability of Early Responses and Achievement of Delayed Responses to Lebrikizumab in Atopic Dermatitis: A 48-Week Japanese Real-World Study.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: February 06, 2026

Hermansky-Pudlak Syndrome Type 3 Complicated by Schizophrenia and Crohn's-Like Colitis.

Hermansky-Pudlak Syndrome Type 3 Complicated by Schizophrenia and Crohn's-Like Colitis.

Journal: The Journal of dermatology

Published: January 18, 2026

Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity.

Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity.

Journal: The Journal of dermatology

Published: January 16, 2026

A Familial Case of CYLD Cutaneous Syndrome With a Novel Nonsense Mutation in Japanese.

A Familial Case of CYLD Cutaneous Syndrome With a Novel Nonsense Mutation in Japanese.

Journal: The Journal of dermatology

Published: January 04, 2026

NLRP3 inflammasome activation is associated with type 1 inflammation and neutrophil activation in pyoderma gangrenosum across human and murine models.

NLRP3 inflammasome activation is associated with type 1 inflammation and neutrophil activation in pyoderma gangrenosum across human and murine models.

Journal: JID innovations : skin science from molecules to population health

Published: December 29, 2025

Effectiveness of Anti-IL-13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48-Week Outcomes by Lebrikizumab and Tralokinumab.

Effectiveness of Anti-IL-13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48-Week Outcomes by Lebrikizumab and Tralokinumab.

Journal: The Journal of dermatology

Published: December 23, 2025

Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study.

Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study.

Journal: The Journal of dermatology

Published: November 22, 2025

Real-World Treatment with Lebrikizumab or Tralokinumab for Atopic Dermatitis: A 60-Week Retrospective Comparative Study.

Real-World Treatment with Lebrikizumab or Tralokinumab for Atopic Dermatitis: A 60-Week Retrospective Comparative Study.

Journal: American journal of clinical dermatology

Published: November 09, 2025

48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients.

48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients.

Journal: American journal of clinical dermatology

Published: October 16, 2025

Showing 1-12 of 133

Last Updated: 09/26/2026